Abstracts tagged "neuropsychiatric disorders"

Abstract Number: 0895 • ACR Convergence 2023
Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus
Chaim Putterman¹, Elise Mike² and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Johns Hopkins, Bronx, NY
Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…
Abstract Number: 1234 • ACR Convergence 2023
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity
Jaqueline de amorim¹, Simone Kishimoto¹, Paula Fernandes¹, Roberto Marini², Zahi Touma³, Hermine Brunner⁴ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil, ²Revista Brasileira de Reumatologia, Campinas, Brazil, ³University of Toronto, Toronto, ON, Canada, ⁴Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
Abstract Number: 1460 • ACR Convergence 2023
Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus
Dionysis Nikolopoulos¹, Nursen Cetrez², Julius Lindblom² and Ioannis Parodis², ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Substantial proportions of systemic lupus erythematosus (SLE) patients report severe fatigue and adverse Health-related Quality of Life (HRQoL). Particularly neuropsychiatric manifestations have been associated…
Abstract Number: 1473 • ACR Convergence 2023
Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades
Ansaam Daoud¹, Loai Dweik², Marina Nighat Magrey³ and Omer Pamuk⁴, ¹University Hospitals, Case Western Reserve University, Akron, OH, ²Cleveland Clinic Akron General, Akron, OH, ³Case Western Reserve University, University Hospitals, Cleveland, OH, ⁴University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: SLE is a chronic autoimmune disease and affects many organ systems. Juvenile onset disease, male sex, renal involvement, and central nervous system involvement are…
Abstract Number: 1478 • ACR Convergence 2023
Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review
Alain Sanchez-Rodriguez¹, Mariana Gonzalez-Treviño¹, Hannah Langenfeld², Cynthia Crowson³, Maria Valenzuela-Almada⁴, Alejandro Rabinstein⁵, Larry J. Prokop⁶, Isabel Valenzuela-Almada⁷ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Department of Pediatrics, Children’s National Medical Center, Washington, DC, ⁵Department of Neurology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁷Division of Internal Medicine, Hospital Medica Sur, Mexico City, Mexico
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…
Abstract Number: 1601 • ACR Convergence 2023
Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Lola Torz², Natalia Petersen², Ayal Ben-Zvi³ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Novo Nordic, Global Obesity Research, Malov, Denmark, ³Hebrew University of Jerusalem, Jerusalem, Israel
Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…
Abstract Number: 1625 • ACR Convergence 2023
Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning
santiago arciniegas¹, Matthias W. Wagner², Logi Vidarsson², Birgit Ertl-Wagner², Tala El Tal³, Asha Jeyanathan², Lawrence Ng², Linda Hiraki², Deborah Levy², George M. Ibrahim² and Andrea Knight², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
Abstract Number: 2056 • ACR Convergence 2023
Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases
Meiqian Ma¹, Erin Masteron² and Jennifer Frankovich¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²University of Washington School of Public Health, Seattle, WA
Background/Purpose: Certain psychiatric conditions are associated with systemic inflammatory processes. We aimed to evaluate whether a pediatric condition characterized by a sudden onset of severe…
Abstract Number: 2303 • ACR Convergence 2023
Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Jaime Vondenberg¹, Chao Zhang¹ and Emily Littlejohn², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…
Abstract Number: 2447 • ACR Convergence 2023
Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Michelle Huang¹, Myriam Meineck², Tamara Möckel², Andreas Schwarting² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) in the form of cognitive deficits, memory loss, depression, and anxiety.…
Abstract Number: 0478 • ACR Convergence 2023
The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children
Maria Grazia Lazzaroni¹, Eleonora Pedretti¹, Liala Moschetti¹, Marzia Bendoni², Lucrezia Visconti², Anna Molinaro², Cecilia Nalli³, Franco Franceschini³, Paolo Airò¹, Jessica Galli², Elisa Fazzi², Angela Tincani⁴ and Laura Andreoli⁵, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ²Unit of Child and Adolescent Neuropsychiatry, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, ⁵University of Brescia, Brescia, Italy
Background/Purpose: The long-term neuropsychiatric (NP) outcome of children born to mothers affected by autoimmune diseases (AIDs) represents a controversial topic, with few studies1-3 reporting a…
Abstract Number: 0550 • ACR Convergence 2023
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL…
Abstract Number: 041 • 2023 Pediatric Rheumatology Symposium
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort
Jaqueline De Amorim¹, Simone Kishimoto¹, Paula Fernandes¹, Roberto Marini¹, Lilian Costallat¹, Zahi Touma², Hermine Brunner³ and Simone Appenzelle⁴, ¹UNICAMP, São Paulo, Brazil, ²University of Toronto, Toronto, ON, Canada, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴University of Campinas, Campinas, Sao Paulo, Brazil
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
Abstract Number: 0321 • ACR Convergence 2022
M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
Eugene Krustev¹, John Hanly², Ricky Chin³, Katherine Buhler¹, Francesca S Cardwell⁴, Murray Urowitz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul R Fortin¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat İnanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵, Marvin Fritzler¹, Ann E Clarke³⁶ and May Choi³⁷, ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ³University of Calgary, Ottawa, ON, Canada, ⁴University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²University College London, London, United Kingdom, ¹³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: We previously reported in a single centre prevalent SLE cohort that antibodies against the cytokinesis-associated protein M-Phase Phosphoprotein 1 (anti-MPP-1) were associated with SLE-related…
Abstract Number: 0332 • ACR Convergence 2022
Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE)
Yoshiyuki Arinuma¹, Yasuhiro Hasegawa², Yu Matsueda², Kenji Oku³ and Kunihiro Yamaoka⁴, ¹Kitasato University, Kanagawa, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Kitasato University, Chigasaki, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Microglial activation is critical for behavioral abnormalities in a mouse model of diffuse NPSLE following anti-glutamate receptor subunit GluN2 antibody (anti-GluN2) exposure to neurons.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].